dshp dsip An Overview of Delivery System Reform Incentive Payment (DSRIP) Waivers Medicaid-Capitated D-SNPs: An Innovative Path – Dual Eligible Special Needs Plans

Certificate of Analysis available per production lot

$HIMS is up nearly 8% after FDA advisers voted to recommend adding BPC-157 to the 503A Bulks List

People with impaired liver or kidney function should use it with caution

Phase 2 Side-Effect Frequencies at 4.5 mg/week (Lancet 2021) Side Effect Nausea Incidence at 4.5 mg/week 47% Side Effect Injection-site reactions Incidence at 4.5 mg/week 43% Side Effect Constipation Incidence at 4.5 mg/week 21% Side Effect Fatigue Incidence at 4.5 mg/week 20% Side Effect Allergic reactions (any) Incidence at 4.5 mg/week 10% Side Effect Vomiting Incidence at 4.5 mg/week 8% Side Effect Loose stools Incidence at 4.5 mg/week 7% Side Effect Headache Incidence at 4.5 mg/week 7% Side Effect Indigestion Incidence at 4.5 mg/week 4% Incidence was lower at lower doses